Financial Performance:
Revenue and Profit/Loss:
- Net Loss: The company reported a significant increase in spending from ordinary activities after tax, which is up 295% to $149,680,539 for the year ended 30 June 2024. This is a substantial increase compared to the previous year.
Net Tangible Assets:
- Per Security: The net tangible assets per security decreased from 2.74 cents in 2023 to 1.15 cents in 2024.
Operational Highlights:
Pipeline Progress:
- Imugene made significant advancements across its oncology assets, including Phase 1 and Phase 1b trials for its key products such as Azer-cel, VAXINIA, and onCARlytics.
- Azer-cel: Progress in Phase 1b trials for Diffuse Large B Cell Lymphoma (DLBCL) patients. This therapy is notable for its potential to be the first approved allogeneic CAR T cell therapy.
- VAXINIA: Early positive signals in Phase 1 trials for solid tumors, receiving FDA Fast Track Designation for bile duct cancer.
- onCARlytics: Initiation of Phase 1 trials combining oncolytic virotherapy with other treatments for advanced solid tumors.
Strategic Moves:
- Acquisition of the Azer-cel allogeneic CD19 CAR T cell therapy program from Precision Biosciences, Inc.
- Partnership with Kincell Bio for the sale of a manufacturing facility, expected to save significant operational costs.
Financial Position:
- Cash Reserves: Reduced from $153,150,662 in 2023 to $93,107,538 in 2024, reflecting increased spending on R&D and acquisitions.
- Capital Raise: Successfully raised $35 million through a placement and an additional $18.2 million via a Share Purchase Plan (SPP).
Management and Corporate Changes:
- Strengthened senior management team with new appointments, including Chief Operating Officer and Chief Medical Officer.
- Forums
- ASX - By Stock
- Ann: Appendix 4E and Annual Report
Financial Performance:Revenue and Profit/Loss:Net Loss: The...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
6.2¢ |
Change
0.003(5.08%) |
Mkt cap ! $455.6M |
Open | High | Low | Value | Volume |
5.8¢ | 6.5¢ | 5.7¢ | $1.751M | 28.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 660964 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 549788 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 660964 | 0.061 |
10 | 1109613 | 0.060 |
3 | 465000 | 0.059 |
8 | 2031160 | 0.058 |
9 | 1210001 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 549788 | 5 |
0.063 | 313635 | 6 |
0.064 | 1129381 | 10 |
0.065 | 1261036 | 13 |
0.066 | 1433220 | 8 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online